Volume 29, Number 1—January 2023
Dispatch
COVID-19 Symptoms by Variant Period in the North Carolina COVID-19 Community Research Partnership, North Carolina, USA
, Ashley H. Tjaden, David Herrington, John Schieffelin, Michael Gibbs, William S. Weintraub, John W. Sanders1, Sharon L. Edelstein1, and on behalf of the COVID-19 Community Research Partnership
Table 1
Overview of demographics and key characteristics of study population in the North Carolina COVID-19 Community Research Partnership study on COVID-19 reinfection, North Carolina, USA*
| Characteristic | Pre-Delta, n = 37,711 | Delta, n = 24,664 | Omicron, n = 19,189 |
|---|---|---|---|
| Median age, y (IQR) |
49 (37–62) |
53 (41–64) |
55 (43–65) |
| Sex | |||
| F | 26,001 (69) | 17,156 (70) | 13,233 (69) |
| M |
11,710 (31) |
7,508 (30) |
5,956 (31) |
| Race | |||
| Asian | 727 (1.9) | 404 (1.6) | 296 (1.5) |
| Black or African American | 2,122 (5.6) | 1,205 (4.9) | 870 (4.5) |
| White | 32,946 (87) | 21,985 (89) | 17,218 (90) |
| Other |
1,916 (5.1) |
1,070 (4.3) |
805 (4.2) |
| Ethnicity | |||
| Other | 3,245 (8.6) | 1,748 (7.1) | 1,266 (6.6) |
| Hispanic or Latino | 942 (2.5) | 562 (2.3) | 442 (2.3) |
| Mixed ethnicity | 500 (1.3) | 317 (1.3) | 239 (1.2) |
| Not Hispanic/Latino |
33,024 (88) |
22,037 (89) |
17,242 (90) |
| Healthcare worker |
10,488 (28) |
6,914 (28) |
5,077 (26) |
| Site | |||
| Atrium | 8,362 (22) | 6,112 (25) | 4,983 (26) |
| Campbell | 744 (2.0) | 450 (1.8) | 259 (1.3) |
| New Hanover | 716 (1.9) | 540 (2.2) | 0 (0) |
| Vidant | 1,367 (3.6) | 692 (2.8) | 0 (0) |
| Wake Forest | 23,475 (62) | 14,628 (59) | 12,122 (63) |
| Wake Med |
3,047 (8.1) |
2,242 (9.1) |
1,825 (9.5) |
| Median no. days reporting during wave (IQR) |
169 (62–326) |
129 (56–167) |
47 (22–57) |
| Vaccination status | |||
| Fully vaccinated by beginning of wave | 1,149 (3.0) | 21,772 (88) | 18,092 (94) |
| Fully vaccinated by end of wave† | 24,264 (64) | 22,597 (92) | 18,112 (94) |
| Boosted by beginning of wave‡ | 0 | 122 (0.5) | 14,595 (76) |
| Boosted by end of wave‡ |
6 (<0.1) |
15,623 (63) |
15,348 (80) |
| COVID-19 positive test§ |
1,908 (5.1) |
1,472 (6.0) |
2,090 (11) |
| Reinfection¶ |
8 (0.4) |
43 (2.9) |
132 (6.3) |
| Vaccine breakthrough infection |
47 (2.5) |
1,233 (84) |
1,936 (93) |
| Booster breakthrough infection | 0 | 360 (24) | 1,444 (69) |
*Values are no. (%) except as indicated. IQR, interquartile range. †>14 days after receipt of first dose if first dose is Johnson & Johnson/Janssen (https://www.jnj.com); >14 days after date of receipt of second dose if first dose is Pfizer-BioNTech (https://www.pfizer.com), Moderna (https://www.modernatx.com), other, or missing. ‡Self-reported receipt of a second dose >60 days following an initial Janssen vaccination or reported a third dose >60 days after the receipt of 2 doses of Pfizer/Moderna/other/missing. §Self-reported. ¶ Self-reported positive test (COVID-19 infection (sample by nasal swab, saliva or spit) >90 days after a prior positive test.
1These senior authors contributed equally to this article.